Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson Sells 27,493 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 27,493 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $16.56, for a total transaction of $455,284.08. Following the transaction, the director now owns 458,506 shares of the company’s stock, valued at approximately $7,592,859.36. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Tyra Biosciences Trading Down 1.7 %

TYRA traded down $0.29 during midday trading on Friday, hitting $16.39. 523,453 shares of the company were exchanged, compared to its average volume of 186,846. The company’s 50 day simple moving average is $22.51 and its 200 day simple moving average is $19.87. The firm has a market capitalization of $865.56 million, a price-to-earnings ratio of -9.69 and a beta of 1.01. Tyra Biosciences, Inc. has a 1-year low of $10.60 and a 1-year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.09. On average, equities analysts anticipate that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on TYRA shares. Wedbush reaffirmed an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Friday, October 25th. HC Wainwright increased their price target on Tyra Biosciences from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Oppenheimer upped their price objective on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, September 19th. Finally, Piper Sandler started coverage on shares of Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Tyra Biosciences currently has an average rating of “Buy” and an average price target of $31.40.

Hedge Funds Weigh In On Tyra Biosciences

Several large investors have recently made changes to their positions in TYRA. RA Capital Management L.P. raised its holdings in Tyra Biosciences by 43.9% in the 1st quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after purchasing an additional 3,180,155 shares during the period. BVF Inc. IL increased its position in shares of Tyra Biosciences by 70.1% in the first quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock valued at $76,444,000 after buying an additional 1,921,599 shares in the last quarter. Perceptive Advisors LLC raised its stake in shares of Tyra Biosciences by 50.5% during the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after buying an additional 338,208 shares during the period. Ally Bridge Group NY LLC acquired a new stake in Tyra Biosciences in the 2nd quarter valued at $4,232,000. Finally, Ensign Peak Advisors Inc purchased a new stake in Tyra Biosciences in the 2nd quarter worth $3,047,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.